Passage Bio Stock Net Income
| PASG Stock | USD 12.58 0.12 0.94% |
As of the 25th of January, Passage Bio holds the Risk Adjusted Performance of 0.1167, semi deviation of 5.89, and Coefficient Of Variation of 680.79. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Passage Bio, as well as the relationship between them. Please check Passage Bio information ratio, value at risk, as well as the relationship between the Value At Risk and expected short fall to decide if Passage Bio is priced some-what accurately, providing market reflects its current price of 12.58 per share. Given that Passage Bio has jensen alpha of 1.05, we recommend you to check out Passage Bio's recent market performance to make sure the company can sustain itself at a future point.
Passage Bio's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Passage Bio's valuation are provided below:Passage Bio does not presently have any trending fundamental ratios for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Is Stock space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Passage Bio. If investors know Passage will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Passage Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Passage Bio is measured differently than its book value, which is the value of Passage that is recorded on the company's balance sheet. Investors also form their own opinion of Passage Bio's value that differs from its market value or its book value, called intrinsic value, which is Passage Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Passage Bio's market value can be influenced by many factors that don't directly affect Passage Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Passage Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Passage Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Passage Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Passage Bio 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Passage Bio's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Passage Bio.
| 10/27/2025 |
| 01/25/2026 |
If you would invest 0.00 in Passage Bio on October 27, 2025 and sell it all today you would earn a total of 0.00 from holding Passage Bio or generate 0.0% return on investment in Passage Bio over 90 days. Passage Bio is related to or competes with NuCana PLC, MetaVia, Lisata Therapeutics, Allarity Therapeutics, CytoMed Therapeutics, Enlivex Therapeutics, and Cingulate. Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases More
Passage Bio Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Passage Bio's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Passage Bio upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 6.75 | |||
| Information Ratio | 0.1375 | |||
| Maximum Drawdown | 58.13 | |||
| Value At Risk | (9.29) | |||
| Potential Upside | 14.59 |
Passage Bio Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Passage Bio's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Passage Bio's standard deviation. In reality, there are many statistical measures that can use Passage Bio historical prices to predict the future Passage Bio's volatility.| Risk Adjusted Performance | 0.1167 | |||
| Jensen Alpha | 1.05 | |||
| Total Risk Alpha | 0.4362 | |||
| Sortino Ratio | 0.1697 | |||
| Treynor Ratio | 0.4932 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Passage Bio's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Passage Bio January 25, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1167 | |||
| Market Risk Adjusted Performance | 0.5032 | |||
| Mean Deviation | 5.76 | |||
| Semi Deviation | 5.89 | |||
| Downside Deviation | 6.75 | |||
| Coefficient Of Variation | 680.79 | |||
| Standard Deviation | 8.34 | |||
| Variance | 69.48 | |||
| Information Ratio | 0.1375 | |||
| Jensen Alpha | 1.05 | |||
| Total Risk Alpha | 0.4362 | |||
| Sortino Ratio | 0.1697 | |||
| Treynor Ratio | 0.4932 | |||
| Maximum Drawdown | 58.13 | |||
| Value At Risk | (9.29) | |||
| Potential Upside | 14.59 | |||
| Downside Variance | 45.61 | |||
| Semi Variance | 34.71 | |||
| Expected Short fall | (6.50) | |||
| Skewness | 1.37 | |||
| Kurtosis | 5.71 |
Passage Bio Backtested Returns
Passage Bio is slightly risky given 3 months investment horizon. Passage Bio maintains Sharpe Ratio (i.e., Efficiency) of 0.15, which implies the firm had a 0.15 % return per unit of risk over the last 3 months. We are able to interpolate and collect thirty different technical indicators, which can help you to evaluate if expected returns of 1.22% are justified by taking the suggested risk. Use Passage Bio Semi Deviation of 5.89, risk adjusted performance of 0.1167, and Coefficient Of Variation of 680.79 to evaluate company specific risk that cannot be diversified away. Passage Bio holds a performance score of 11 on a scale of zero to a hundred. The company holds a Beta of 2.46, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Passage Bio will likely underperform. Use Passage Bio expected short fall, and the relationship between the value at risk and daily balance of power , to analyze future returns on Passage Bio.
Auto-correlation | 0.36 |
Below average predictability
Passage Bio has below average predictability. Overlapping area represents the amount of predictability between Passage Bio time series from 27th of October 2025 to 11th of December 2025 and 11th of December 2025 to 25th of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Passage Bio price movement. The serial correlation of 0.36 indicates that just about 36.0% of current Passage Bio price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.36 | |
| Spearman Rank Test | 0.72 | |
| Residual Average | 0.0 | |
| Price Variance | 9.6 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Passage Bio reported net income of (64.77 Million). This is 118.98% lower than that of the Biotechnology sector and 192.46% lower than that of the Health Care industry. The net income for all United States stocks is 111.34% higher than that of the company.
Passage Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Passage Bio's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Passage Bio could also be used in its relative valuation, which is a method of valuing Passage Bio by comparing valuation metrics of similar companies.Passage Bio is currently under evaluation in net income category among its peers.
Passage Fundamentals
| Return On Equity | -0.87 | |||
| Return On Asset | -0.32 | |||
| Current Valuation | 11.55 M | |||
| Shares Outstanding | 3.18 M | |||
| Shares Owned By Insiders | 0.21 % | |||
| Shares Owned By Institutions | 51.91 % | |||
| Number Of Shares Shorted | 19.54 K | |||
| Price To Book | 1.28 X | |||
| EBITDA | (62.09 M) | |||
| Net Income | (64.77 M) | |||
| Cash And Equivalents | 239.25 M | |||
| Cash Per Share | 4.39 X | |||
| Total Debt | 25.48 M | |||
| Debt To Equity | 0.11 % | |||
| Current Ratio | 9.23 X | |||
| Book Value Per Share | 9.79 X | |||
| Cash Flow From Operations | (47.96 M) | |||
| Short Ratio | 0.41 X | |||
| Earnings Per Share | (14.62) X | |||
| Target Price | 39.6 | |||
| Number Of Employees | 60 | |||
| Beta | 1.76 | |||
| Market Capitalization | 39.99 M | |||
| Total Asset | 102.41 M | |||
| Retained Earnings | (659.24 M) | |||
| Working Capital | 59.45 M | |||
| Current Asset | 144.91 M | |||
| Current Liabilities | 3.09 M | |||
| Net Asset | 102.41 M |
About Passage Bio Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Passage Bio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Passage Bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Passage Bio based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether Passage Bio is a strong investment it is important to analyze Passage Bio's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Passage Bio's future performance. For an informed investment choice regarding Passage Stock, refer to the following important reports:Check out Passage Bio Piotroski F Score and Passage Bio Altman Z Score analysis. For more detail on how to invest in Passage Stock please use our How to Invest in Passage Bio guide.You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Is Stock space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Passage Bio. If investors know Passage will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Passage Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Passage Bio is measured differently than its book value, which is the value of Passage that is recorded on the company's balance sheet. Investors also form their own opinion of Passage Bio's value that differs from its market value or its book value, called intrinsic value, which is Passage Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Passage Bio's market value can be influenced by many factors that don't directly affect Passage Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Passage Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Passage Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Passage Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.